EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
Pharmabiz14h
EMA committee recommends marketing approval for AbbVie’s mirvetuximab soravtansine for the treatment of certain adult ovarian cancer
North Chicago, Illinois Monday, September 23, 2024, 13:00 Hrs [IST] ...
Too Old to Operate17h
Trends and gender disparities in the incidence of rheumatic diseases: a regional study from 2018 to 2021.
Rheumatic diseases encompass a range of entities affecting the musculoskeletal system and connective tissue due to immune dysregulation. These entities include rheumatoid arthritis, systemic lupus ...
Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket
The surge in global cancer cases is raising serious concerns among experts. A recent study published in Monday in Cancer, a ...
The Pharma Letter3d
Latest batch of EMA’s human medicines committee recommendations
Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...
AbbVie: CHMP Adopts Positive Opinion For Mirvetuximab Soravtansine - Quick Facts
AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...
Abbvie Slides on ELAHERE Opinion of its Cancer Treatment
AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...
Medscape3d
Conjugated Antibodies: Emerging Star in Ovarian Cancer Tx
Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...
AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...
The American Journal of Managed Care8d
Dr Angeles Alvarez Secord on "Exciting" Responses With Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer
Mirvetuximab soravtansine showed high evidence of efficacy in heavily pretreated FRα-positive, platinum-sensitive ovarian ...
PipelineReview.com13d
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
NORTH CHICAGO, IL, USA I 9, 2024 I AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will ...
Morningstar14d
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
Full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating mirvetuximab soravtansine (ELAHERE®), for high folate receptor-alpha (FRα) expressing platinum ...